Clinical Trial Update: Rituximab for Prevention of Rejection After Renal Transplantation [Phase 2, Phase 3]

View source ↗

Summary

Rituximab evaluated to prevent rejection after kidney transplantation in Phase 2 and Phase 3 trials; the studies are reported as completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Transplantation

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: Radboud University Medical Center | Conditions: Kidney Transplantation | Phase 2, Phase 3 | Status: COMPLETED